Skip to Content

Join the 'Epoetin Alfa' group to help and get support from people like you.

Epoetin Alfa News

FDA Approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the Treatment of Anemia

May 15, 2018 – The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney...

FDA Medwatch Alert: Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication - Modified Dosing Recommendations

Epoetin alfa (marketed as Epogen and Procrit) and darbepoetin alfa (marketed as Aranesp) ISSUE: FDA notified healthcare professionals that new, modified recommendations for more conservative dosing...

Ask a Question

Want to post your own question to this support group? You'll need to first create an account with Drugs.com (or sign in to your existing account).

Further Information

Related Condition Support Groups

Anemia

Epoetin Alfa Patient Information at Drugs.com